Evidence map›Paper›PMID 37297971›Full record

ArticleJournal of clinical medicine2023

Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a Retrospective Mono Institutional Study.

Giuseppe Facondo, Mattia Serio, Gianluca Vullo, Maria Paola Bianchi, Sabrina Pelliccia, Alice Di Rocco, Tiziana Lanzolla, Maurizio Valeriani, Arianna Di Napoli, Agostino Tafuri and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Giuseppe FacondoDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy.
Mattia SerioDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy.
Gianluca VulloDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0002-2521-1088
Maria Paola BianchiHematology Institute, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, Italy.
Sabrina PellicciaHematology Institute, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, Italy.
Alice Di RoccoDepartment of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, Italy.
Tiziana LanzollaNuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, Italy.
Maurizio ValerianiDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0002-1670-3005
Arianna Di NapoliPathology Unit, Department of Clinical and Molecular Medicine, Sapienza University of Rome, St. Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0002-3159-5380
Agostino TafuriDepartment of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, Italy.
Maurizio MartelliDepartment of Translational and Precision Medicine, Hematology Institute, Sapienza University of Rome, Umberto I, 00189 Rome, Italy.
Mattia Falchetto OstiDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0002-8996-5559
Vitaliana De SanctisDepartment of Medicine and Surgery and Translational Medicine, Sapienza University of Rome, Radiotherapy Oncology, St. Andrea Hospital, 00189 Rome, Italy.ORCID 0000-0002-1273-834X
Sapienza University of Rome · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT).

methodsThirty-one patients with PMBCL were recruited. After completion of R-ICHT, patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and were treated with adjuvant RSRT. The chosen techniques for RT delivery were intensity-modulated radiation therapy (IMRT) or three-dimensional conformal RT (3D-CRT). Most patients underwent the first one using cone-beam computed tomography (CBCT). All patients were evaluated every 3 months for the first 2 years and every 6 months afterwards for a period of at least 5 years, with clinical and radiological procedures as required.

resultsAll patients received RSRT with a dose of 30 Gy in 15 fractions. The median follow-up time of 52.7 months (IQR: 26-64.1 months). The 5-year OS rate was 100%. The 2-year and 5-year PFS rates were 96.7% and 92.5%, respectively. Patients with relapsed disease had been treated with high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT).

conclusionRSRT in patients with PMBCL treated with ICHT and DS 4 did not impact unfavorably on patient survival.

Indexed as

lymphomaprimary mediastinal lymphomaradiotherapyresidual site radiation therapy

Identifiers

PMID37297971
PMCPMC10253997
OpenAlexW4378908668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.